ClinicalTrials.gg
CompletedNCT00541229Updated May 12, 2017Results posted

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

A Phase 1 interventional study of sitagliptin phosphate and sitagliptin phosphate in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
98th of 197
103 · median 102
Started
2007
with 16 others
Phase 1
23 of 198
none open now
Registered
34th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 98th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 23 in phase 1, and was the 34th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has Type 2 Diabetes
  • Patient is between the ages of 30-65 years
  • Patient is not on an antihyperglycemic agent (AHA) (glycosylated [] 7-10% ), or is on oral single AHA or low-dose combination therapy (A1C 6.5-9.5%).

Exclusion criteria

Exclusion Criteria:

  • Patient has Type 1 Diabetes
  • Patient has been treated with sitagliptin, vildagliptin, or other similar drugs or has been treated with exenatide in the past 3 months
  • Patient has taken insulin within the past 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    1

    sitagliptin 100 mg

    Drug: sitagliptin phosphate

  • Experimental
    2

    sitagliptin 200 mg

    Drug: sitagliptin phosphate

  • Placebo comparator
    3

    Placebo

    Drug: Comparator: Placebo

Interventions

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    sitagliptin 100 mg tablets q.d. (once daily) for 7 days.

    Also known as: MK0431

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    sitagliptin 200 mg tablets q.d. (once daily) for 7 days.

    Also known as: MK0431

  • DrugComparator: Placebo

    sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.

06

What researchers measure

Primary outcomes

  1. 24-hour Weighted Mean Glucose (WMG)

    The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC(0-24 hr)) divided by 24 using linear trapezoidal method.

    Time frame: Day 7 of Treatment Period I. Due to a carry-over effect that was observed between treatment periods, efficacy results are presented from Treatment Period I only.

07

Results

Posted Jul 28, 2009
Limitations and caveats
The pre-specified rule for non-superiority of sitagliptin 200 mg compared with 100 mg was met at the planned interim analysis. As such, the trial was terminated as pre-specified.

Participant flow

First Patient In: 17-Oct-2007; Last Patient Last Visit: 01-Jul-2008; Seventeen medical clinics worldwide (8 in the United States, 8 in Europe and 1 in Mexico).

Treatment Period I (Week 1)
Participant flow — Treatment Period I (Week 1)
MilestonePlacebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / Placebo
Started171620181418
Completed171517171416
Not completed013102
Withdrew: Physician decision001000
Withdrew: Withdrawal by subject000001
Withdrew: Protocol specified criteria000001
Withdrew: Study terminated by sponsor012100
Washout Period I (Week 2-5)
Participant flow — Washout Period I (Week 2-5)
MilestonePlacebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / Placebo
Started171517171416
Completed131313131311
Not completed424415
Withdrew: Adverse event101000
Withdrew: Physician decision000100
Withdrew: Protocol violation000001
Withdrew: Study terminated by sponsor323314
Treatment Period II (Week 6)
Participant flow — Treatment Period II (Week 6)
MilestonePlacebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / Placebo
Started131313131311
Completed11121212118
Not completed211123
Withdrew: Protocol violation000011
Withdrew: Study terminated by sponsor211112
Washout Period II (Week 7-10)
Participant flow — Washout Period II (Week 7-10)
MilestonePlacebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / Placebo
Started11121212118
Completed7810875
Not completed442443
Withdrew: Protocol violation100000
Withdrew: Withdrawal by subject000010
Withdrew: Study terminated by sponsor342433
Treatment Period III (Week 11)
Participant flow — Treatment Period III (Week 11)
MilestonePlacebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / Placebo
Started7810875
Completed789864
Not completed001011
Withdrew: Adverse event000010
Withdrew: Protocol specified criteria000001
Withdrew: Study terminated by sponsor001000

Outcome measures

Primary24-hour Weighted Mean Glucose (WMG)

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC(0-24 hr)) divided by 24 using linear trapezoidal method.

Time frame:
Day 7 of Treatment Period I. Due to a carry-over effect that was observed between treatment periods, efficacy results are presented from Treatment Period I only.
Reported as:
Least squares mean · mg/dL
24-hour Weighted Mean Glucose (WMG)
mg/dLSitagliptin 200mgSitagliptin 100mgPlacebo
24-hour Weighted Mean Glucose (WMG)169.1 (153.8 to 184.4)159.0 (143.1 to 174.9)200.9 (186.1 to 215.7)
Statistical analysis
  • Sitagliptin 200mg vs Placebo · ANOVA · p = 0.004 · Mean difference (final values): -31.8 · 95% CI -53.1 to -10.5Model term: treatment
  • Sitagliptin 100mg vs Placebo · ANOVA · p = <0.001 · Mean difference (final values): -41.9 · 95% CI -63.6 to -20.2Model term: treatment
  • Sitagliptin 200mg vs Sitagliptin 100mg · Mean difference (final values): 10.1 · 80% CI 0.61 to 9999999This is a 1-sided 80% confidence interval and the upper bound 9999999 was used here to indicate positive infinity.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 200 mg—0/78 (0%)4/78 (5.1%)
Sitagliptin 100 mg—0/72 (0%)2/72 (2.8%)
Placebo—0/74 (0%)4/74 (5.4%)
Most frequent other events
Most frequent other events
EventSitagliptin 200 mgSitagliptin 100 mgPlacebo
HeadacheNervous system disorders4/782/724/74

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / PlaceboTotal
Mean54.5 ± 8.456.6 ± 5.855.7 ± 7.255.3 ± 8.350.0 ± 10.048.6 ± 9.653.5 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / PlaceboTotal
Female55744328
Male12111314101575
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / PlaceboTotal
White12141515111279
Asian0000011
Other52533523
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)Placebo / 100 mg / 200 mg100 mg / 200 mg / Placebo200 mg / Placebo / 100 mgPlacebo / 200 mg / 100 mg100 mg / Placebo / 200 mg200 mg / 100 mg / PlaceboTotal
Mean179.3 ± 32.1167.0 ± 41.1184.0 ± 42.1173.2 ± 43.2158.5 ± 17.3166.0 ± 36.5172.0 ± 36.9
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514. PubMed 19691426 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Jun 2008, 9 months.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2007
First posted
Oct 10, 2007
StartActual
Aug 24, 2007
Primary completionActual
Jun 17, 2008
CompletionActual
Jul 1, 2008
Results first posted
Jul 28, 2009
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00541229
Responsible party
Sponsor
First posted
Oct 10, 2007
Start date
Aug 24, 2007
Primary completion
Jun 17, 2008
Completion
Jul 1, 2008
Results posted
Jul 28, 2009
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion